Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MGLL | Q99685 | 3/20 | 0.47 |
| ▸ | FAAH | O00519 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CCR8 | P51685 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 1/20 | 0.46 |
| ▸ | TNKS | O95271 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL896968 | 0.87 | FAAH (0.63) | MGLLFAAHCCR8KCNH2 | |
| SCHEMBL21276348 | 0.85 | MGLL (0.53) | CYP2D6ALDH1A1MGLLCYP3A4TSHR | |
| SCHEMBL8060461 | 0.84 | CYP2D6 (0.67) | CYP2D6ALDH1A1MGLLCYP3A4TSHR | |
| SCHEMBL20490879 | 0.82 | FAAH (0.61) | MGLLFAAHCCR8KCNH2 | |
| SCHEMBL30758661 | 0.82 | FAAH (0.61) | MGLLFAAHCCR8KCNH2 | |
| SCHEMBL8044838 | 0.79 | CYP2D6 (0.77) | CYP2D6ALDH1A1CYP3A4TSHR | |
| SCHEMBL1426231 | 0.79 | CYP2D6 (0.64) | CYP2D6ALDH1A1CYP3A4TSHR | |
| SCHEMBL27477846 | 0.79 | CYP2D6 (0.62) | CYP2D6ALDH1A1CYP3A4TSHR | |
| SCHEMBL20556708 | 0.79 | ERN1 (0.56) | CYP2D6MGLLCYP3A4TSHRRORC | |
| SCHEMBL21262272 | 0.78 | CYP2D6 (0.60) | CYP2D6ALDH1A1CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120083476-A1 | HETEROARYL-SUBSTITUTED SPIROCYCLIC DIAMINE UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-05 | — | — | US | disclosed |
| WO-2010141817-A1 | HETEROARYL-SUBSTITUTED SPIROCYCLIC DIAMINE UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083476-A1 | HETEROARYL-SUBSTITUTED SPIROCYCLIC DIAMINE UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, DBH | CYP2D6 1098/4885ALDH1A1 709/4885MGLL 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.